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Enhancement of paclitaxel activity against
hormone-refractory prostate cancer cells in vitro
and in vivo by quinacrine
PL de Souza, M Castillo* and CE Myers
Division of Hematology/Oncology, Box 513, University of Virginia, Charlottesville, VA 22908, USA
Summary Cytoplasmic phospholipase A2 (PLA2) is known to be phosphorylated and activated by MAP kinase (Lin et al 1993, Cell 72:
269-278), an important downstream component of signal transduction, whereas paclitaxel has been shown to inhibit isoprenylation of ras
proteins (Danesi et al 1995, MolPharmacol47: 1106-1111). Given that quinacrine (Q), a PLA2 inhibitor, and paclitaxel (P) might act at different
sites in the cell signalling pathway, our aim was to test whether they were synergistic in combination against prostate cancer cells. Cell viability
of PC-3, PC-3M and DU145 cells in 96 - well plates was assessed 96 h after drugs were added concurrently. Using Chou analysis, we
demonstrated synergy for the combination against all three cell lines. Further, synergy was present under both conservative (mutually non-
exclusive) and non-conservative (mutually exclusive) models. Studies in the nude mouse xenograft model support the finding of synergy in
vitro. In DU145-bearing mice, Q (50 mg kg-') and P (0.5 mg kg-') given daily for 12 consecutive days, either concurrently or sequentially, was
more effective than either drug alone, at twice the dose intensity. In an enzyme-linked immunosorbent (ELISA) apoptosis assay, arachidonic
acid was able to partially reverse Q- and P-induced apoptosis, suggesting PLA2 pathway involvement. Finally, the combination of lovastatin,
another inhibitor of ras isoprenylation, and quinacrine had synergistic inhibitory effects on the growth of PC-3 cells in vitro, suggesting that the
combination of these two classes of compounds might serve as an attractive therapeutic approach for prostate cancer.
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Despite intensive investigation, there is still no chemotherapy
regimen that is reliably superior for the treatment of hormone-
refractory prostate cancer (HRPC). Recently, Hudes et al (1995)
showed that estramustine in combination with paclitaxel was able
to reduce serum prostate-specific antigen (PSA) levels to at least
50% of baseline values in 23 evaluable patients with HRPC and
concluded that the two agents might have been acting synergisti-
cally on complementary sites on the microtubule. Paclitaxel (P)
stabilizes microtubules (Schiff et al, 1979; Schiff and Horwitz,
1980), but recent evidence suggests that it can also inhibit
isoprenylation of ras proteins (Danesi et al, 1995), thereby
perturbing ras signalling. We hypothesized that the responses seen
in the study by Hudes et al (1995) may have been caused in part by
this mechanism of action of paclitaxel. Therefore, we reasoned
that paclitaxel might act synergistically with another agent that
could inhibit a different portion ofthe ras signalling pathway.
Quinacrine (Q) is an anti-malarial agent that has been largely
superseded but is still available for the treatment of giardiasis
(Babb, 1995) and lupus (Wallace, 1994). It is able to modulate drug
resistance (Ford et al, 1989) and inhibit phospholipase A2 (PLA2)
action. PLA2 hydrolyses the sn-2-acyl bondofmembrane phospho-
lipids to produce arachidonic acid, which has been implicated in a
variety of signal transduction events, including malignant cell
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proliferation (Tokumoto et al, 1993; Hanada et al, 1995). Further,
histological studies suggest that membrane PLA2 expression is
associated with the aggressiveness of tumour type, at least in
gastric (Yamashita et al, 1994) and breast cancer (Murata et al,
1993). The regulation of cytoplasmic PLA2 (cPLA2) is complex,
but the enzyme is known to be phosphorylated and activated by
MAP kinase (Lin et al, 1993), which is itselfadownstream compo-
nent ofras cellular signalling.
Given that both quinacrine and paclitaxel act on different
portions ofthe ras signalling pathway oftumour cells, we hypoth-
esized that the quinacrine could enhance the growth-inhibitory
effects ofpaclitaxel. Our aim was to draw together these observa-
tions from the signal transduction field and evaluate in a pre-
clinical setting, using prostate cancer as a translational paradigm,
whether these drugs in combination might be worth testing in
the clinic.
METHODS
Drugs
Quinacrine (ICN Chemicals, Aurora, OH, USA) was diluted with
RPMI-1640 medium (Biowhittaker, Walkersville, MD, USA) into
aliquots at a stock concentration of 1 mm for the in vitro experi-
ments and stored at-20°C. Paclitaxel (Biomol, Plymouth Meeting,
PA, USA) was dissolved in 100% ethanol and stored at-20°C. The
lactone form of lovastatin (a gift from Merck Sharp & Dohme,
Rahway, NJ, USA) was prepared as described previously (Fenton
et al, 1992) and a 10 ,UM stock solution was stored at-20°C. For in
vivo experiments, appropriate amounts of Q were dissolved in
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sterile water each week and stored at 4°C between dailytreatments,
while P was prepared in a cremaphor-ethanol-0.9% sodium
chloride solution at a ratio of 1:1:18 (v/v/v).
In vitro dose-response experiments
PC-3, PC-3M and DU145 (American Type Culture Collection,
Rockville, MD, USA) were maintained in logarithmic growth
phase in tissue culture flasks (Nunc Inc., Naperville, IL, USA)
containing RPMI-1640 medium supplemented with 10% fetal
bovine serum under standard tissue culture conditions (5% carbon
dioxide, 37°C, 95% humidity). A series of 96-well plates (Falcon,
Becton Dickinson, Lincoln Park, NJ, USA) were seeded with 2000
cells per well in 100 ,ul of medium and incubated overnight to
allow attachment ofcells. Initially, Q alone (1-20gM) and P alone
(1-100 nM) were used to establish baseline growth inhibition. In
later experiments, Q was used as the background drug at a single
concentration for each plate, while P concentrations were varied
within the plate. In total, 25 combinations of Q (0.1, 0.5, 1, 5 and
10gM) and P (0.5, 1, 5, 10 and 50 nM) were assessed (n = 12 wells
each). Ethanol was added in appropriate amounts to equalize
vehicle concentration for all wells, including controls, and was
always less than 0.5%. In otherexperiments with PC-3, the combi-
nation of lovastatin (0.1-10 gM) with Q (0.1-10 gM) concurrently
was assessed for synergistic activity as described above and below.
The CellTiter 96 aqueous non-radioactive cell proliferation assay
(Promega Corporation, Madison, WI, USA), a modification ofthe
MTT assay, was used to quantify inhibition ofgrowth.
Synergy assessed by isobologram
The inhibitory concentration (IC) at 25% (IC25), 50% (IC50) and
75% (IC75) ofcontrol values for each drug alone at 96 h was calcu-
lated by computer program (Chou and Chou, 1987). These values
were chosen because they represented the linear section of the
dose-response curves for both drugs. The corresponding, experi-
mentally derived, IC values for both drugs in combination were
then plotted and compared against the line of identity for each
drug alone required to produce the same inhibitory effect. Points
falling below and above the line of identity are therefore defined
as representing synergy and antagonism respectively.
Synergy assessed by Chou analysis
This method has been described previously (Chou et al, 1994).
Briefly, a computer program (Chou and Chou, 1987) based on the
median effect principle was used to calculate combined drug
effects: FaIFU = (D/Dm)m, where Fa is the fraction affected by doseD
(compared with control),Fu is the fraction unaffected (=1- Fa), D is
the dose, Dm is the dose required for 50% effect (i.e. IC50) and m is
the coefficient of the sigmoidicity of the dose-effect curve (Chou,
1976). Following this, the combination index (CI)-isobologram
equation was used for data analysis of two-drug combinations
(Chou and Talalay, 1977, 1984), where CI < 1, CI = 1 and CI < 1
indicate synergism, additive effect and antagonism respectively.
Detection of apoptosis
This procedure has been described previously (Danesi et al, 1995).
Briefly, PC-3M cells were seeded in 100-mm Petri dishes
(Falcon), incubated overnight and treated with Q and P. Controls
(no drug treatment) were also prepared. At 20-22 h after drug
addition, cells were harvested and lysed with hypotonic lysis
buffer (10 mM Tris, 1 mM EDTA, pH 7.5) containing 0.5% (v/v)
Triton X-100 for 60 min at 4°C, centrifuged and the supernatant
was stored at -20°C. The supernatant, containing apoptotic DNA,
was extracted, precipitated, centrifuged and recovered DNA was
then washed with 70% ethanol and dried in a vacuum evaporator.
After resuspension in 10 mm Tris, 1 mM EDTA, pH 7.4, and
heating, DNA was subjected to electrophoresis in a 1% agarose gel
containing 40 mm Tris-acetate, 1 mM EDTA, pH 8. Bands were
visualized by ethidium bromide staining and photographed with a
Polaroid camera after UV illumination. A 123-bp DNA ladder was
run as a standard.
To quantitate apoptosis, we followed the manufacturer's
instructions for the Cell Death Detection ELISA kit (Boehringer
Mannheim, Indianapolis, IN, USA). Briefly, PC-3 cells were
seeded and treated with Q and P atfinal concentration ratios of(Q)
2.5 gM: (P) 25 nm or (Q) 15 gM: (P) 150 nm, or Q or P alone at
twice the concentrations used for the combination. In otherexperi-
ments, arachidonic acid at a final concentration of 5 gM was also
added to the medium. Lysed cell samples were assayed for protein
concentration by the bicinchoninic acid method (BCA protein
assay, Pierce, Rockford, IL, USA), corrected for protein content
and loaded into wells precoated with anti-histone antibody. After
the final washing step, the absorbance of the colour change
induced by substrate in reaction with the peroxidase-linked
secondary antibody was recorded by a plate reader at 504 nm.
Results are expressed as absorbances as a percentage of control
(cells treated with drug vehicle only), where > 100% indicates the
presence ofapoptotic DNA.
Xenografts
For each cell line, 2 x 106 cells, together with Matrigel, were
injected subcutaneously (s.c.) into each flank of each mouse in a
total volume of 200 gl per injection (50% cell suspension in
RPMI-1640: 50% Matrigel). Matrigel was used to improve the
'take' rate (Pretlow et al, 1991). Tumours were monitored for
growth before mice were randomized to groups on day 5 (DU145
and PC-3M) or day 7 (PC-3). Tumour volume (TV) was calculated
according to the formula TV = (length x width2)/2. This formula
has previously been shown to correlate very well with excised
tumour weight (PL de Souza et al, unpublished data). All animal
experiments were carried out with the approval of the Animal
Ethics Committee of the University of Virginia and monitored
according to established guidelines.
Design of in vivo experiments
Three separate experiments were carried out in athymic mice
(Harlan Sprague Dawley, Indianapolis, IN, USA), one for each
cell line: DUI45, PC-3 and PC-3M. In the first experiment, 39
male mice bearing DU145 xenografts were randomized into five
groups, comprising control (C, sterile water daily), quinacrine
alone (Q, 100 mg kg-' daily), paclitaxel alone (P, 1 mg kg-' daily),
quinacrine and paclitaxel given concurrently (QP concurrent,
Q 50 mg kg-' + P 0.5 mg kg-' daily) and quinacrine and paclitaxel
given sequentially (QP sequential, Q 100 mg kg-' on day 1, then
P 1 mg kg-' on day 2, alternated daily). Sterile water or Q was
given by oral gavage through animal feeding needles (Popper &
Sons, New Hyde Park, NY, USA), whereas P was given by bolus
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Figure 1 Isobolograms for the combination of quinacrine and paclitaxel
against PC-3 (A), PC-3M (B) and DU145 (C). The isobols for IC25 (0), IC50
(U) and IC75 (A) are plotted with quinacrine concentration (gM) along the
abscissa and paclitaxel concentration (nM) along the ordinate. Forclarity,
only the line of additivity (-- --) for the IC75 values is plotted. (B) and (C)
contain overlapping symbols
Table 1 Concentration-effect parameters for quinacrine (Q) and paclitaxel
(P) against three hormone-independent prostate cancer cell lines
Cell line Drug Dm (,UM) m r n
PC-3 Q 3.08+ 1.06 2.12 + 0.55 0.97 24
P 0.021 + 0.0088 1.64+ 0.33 0.90 24
PC-3M Q 4.73 + 1.36 3.99 ± 1.25 0.97 24
P 0.017±0.0013 1.51 ± 0.29 0.93 24
DU145 Q 3.45 + 0.24 2.64+ 0.01 0.91 12
P 0.010 + 0.0024 2.08 + 0.32 0.93 12
The parameters Dm, m and rare the antilog of the abscissa, slope and the
linear correlation of the median effect plot, which indicate the potency of the
drug (IC50), the shape of the concentration-effect curve and the conformity of
the data to the mass-action law respectively (Chou et al, 1994). The number
of estimations of the effect of each concentration combination is indicated by
n. Values are means ± standard errors.
intravenous injection. All volumes delivered were 200 ,ul, regard-
less of route, and mice were treated for 12 consecutive days.
Actual drug dosages for each group were calculated according to
the most recent average weight available for each group, obtained
twice weekly. In the second experiment, 36 PC-3-bearing mice
were randomized in to four groups: C, Q, P or QP concurrently. Q
was given on a daily x 5 schedule, with 2 days off, for a total 14
days, and P was given only once a week. In a similar design, 40
PC-3M-bearing mice were given P daily for 5 days, with 2 days
off, for 14 days, while the Q schedule remained the same.
Derivation of drug doses used for in vivo experiments
Q doses were determined from previous experiments. P doses were
chosen to provide blood levels of approximately 1 gmU to simulate
concentrations typically achievable by 24-h infusion (Jamis-Dow
et al, 1993) and were based on earlier work on the pharmaco-
kinetics of paclitaxel in nude mice (Eiseman et al, 1994). Doses
were halved for each drug in the QP groups in the hope that if the
combination proved to be as or more effective than either agent
alone at double the dose, we could conclude that the combination
showed at least additive activity. This reasoning was based on the
CI-isobologram equation derived by Chou and Talalay (1984):
CI = (Dcomb)I/(Dalone)l + (Domb),I(Dalone)2 + a(Dcomb)I (Dcomb)2/
(Dalone) (Dalone)2
where (Dalone) is the dose of drug 1 alone required for a given
effect (fa), (D omb),is the dose ofdrug 1 in the combination required
for a given effect (fa), (Da,one)2 is the dose ofdrug 2 alone required
for a given effect (f ), (Dcom )2 is the dose of drug 2 in the combi-
nation required for a given effect (f), CI is the combination index,
a measure of the degree of synergy, and ax = 0 if the effects of the
two drugs are mutually exclusive (Chou, 1991; Chou and Chou,
1987). Let (Dlone)1 = some concentration p, (Dal)l = some
concentration q, (Dcomb)1 = O.5p and (Dcomb)2 = 0.5q, then
CI = O.SpIp + 0.SqIq + a(O.5p)(0.5q)Ipq
= 0.5 + 0.5 + oa(O.25)pqlpq
Ifthe term a = 0, which is likely given the different mechanisms of
action ofQ and P, then CI = 1, which is the definition ofadditivity.
This principle is also used in the procedures for quantifying
apoptosis described above, where combination doses are 50% of
the doses used for each drug as a single agent.
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Figure 2 Combination index values, derived from Chou analysis, for varying
concentration ratios of quinacrine and paclitaxel. Experiments are grouped
according to the background quinacrine concentrations per 96-well plate
(0.1 gM, 0; 0.5 gM, *; 1 gM, A; 5 lM, V; 10 gM, *), to each of which five
concentrations of paclitaxel (0.5 - 50 nM) were added
Statistical methods
Repeated measures analysis ofvariance (RMANOVA) was used to
analyse the differences in tumour size in mice overtime (Heitjan et
al, 1993). When multiple groups were compared, a one-way
ANOVA was used to establish a significant difference among
groups first, before comparing specific pairs. In the case of non-
normally distributed groups, non-parametric methods were used to
examine statistical significance. Unless otherwise specified, other
statistical comparisons were also made by ANOVA. SigmaStat for
Windows (Jandel Scientific, San Rafael, CA, USA) was used for
statistical calculations.
RESULTS
In vitrodose-responseexperiments
A concentration- andtime-dependent effect on cellviability exists
for both Q and P alone against all three hormone-refractory
prostate cancer cell lines tested(data notshown). At 96h, the IC50s
forQ alone were 3.1, 4.7 and 3.5 gm forPC-3, PC-3M and DU145
respectively, whereas the coffesponding IC50s for P were 21, 17
and 10 nmrespectively (Table 1).
Synergyanalysis by isobologram methods
Figure I(A-C) demonstrates the synergistic activity of non-
constant dose ratios of Q and P for PC-3, PC3M and DUI45
respectively. In general, the curves for IC25' IC50 and IC75 all show
the same concave appearance, relative to the line of identity for
each IC value.Only the IC75 lineofidentity is shown inFigure I for
illustration. Overall, these results indicatesynergismforthe combi-
nation ofQ and P at non-constant ratios forthe three cell lines.
v
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Figure 3 Effect of sequence ofdrug administration on cell viability for
PC-3 (A), PC-3M (B) and DU145 (C). Quinacrine alone was added to wells
for 24 h, followed by 24 h paclitaxel (0) orthe reverse (0) in varying molar
ratios (abscissa), and cell viability was assayed at 48 h. Error bars represent
the s.e.m.
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Figure 4 Apoptosis induced in PC-3M cells. Lane designations are: 123-bp
DNA ladder standard (lane 1); controls (no drug, lane 2); 100 nM paclitaxel
alone (lane 3); 30 gM quinacrine alone (lane 4); and 10gM quinacrine with
10 nM paclitaxel (lane 5). DNA was loaded on a 1% agarose gel containing
ethidium bromide, subjected to electrophoresis and photographed with a
polaroid camera
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Synergy assessed by Chou analysis
By Chou analysis, most combination dose ratios of Q and P
produced marked synergy, under both mutually exclusive and
mutually non-exclusive conditions (data not shown), although
apparent antagonism also occurred. Increasing doses ofboth drugs,
in general, produces more growth inhibition (higher Fa), but
synergy becomes more apparent at higher Q doses (5-10 gM),
where the combination index was less than one for all dose combi-
nations tested. Figure 2 plots the combination index (CI) values for
a variety ofQ/Pratios, grouped by varying background Q levels. In
general, the higherQ levels (5 and 10gM) are associated with more
consistent synergism across the range of P levels tested, although
synergism is seen with Q concentrations as low as 0.1JIM. At the
lower Q doses (0.1, 0.5 and 1 gM), lower P doses are associated
with antagonism. Taken together, these results suggest that a
minimum threshold Q concentration ofbetween 0.1 and 0.5 gM is
required for synergy, and at this range P concentrations between 5
and 50 nm appear to be associated with the most synergy.
Effect of sequence of drug administration on cell
viability
Figure 3 depicts the effect on cell viability of changing the
sequence of drug administration from 24 h Q followed by 24 h P,
and the reverse. At 48 h, there is no effect of the sequence of
administration ofdrugs on cell viability forPC-3M or DU145. The
degree of growth inhibition of PC-3 cells increases when P is
given before Q.
Synergy of quinacrine- and paclitaxel-induced
apoptosis
Figure 4 demonstrates apoptosis ofPC-3M cells induced by 30gM
Q alone, 100 nM P alone and the combination of 10 gM Q with
10 nM P. Despite a markedly reduced dose ofboth drugs in combi-
nation, DNA fragmentation is still visible, indicating that the
combination may be synergistic in inducing apoptosis. This obser-
vation was confinned by an ELISA method, in which 2.5 ,UM Q
combined with 25 nM P produced as much apoptosis as 5 ,UM Q
alone and more apoptosis than 50 nM P alone (data not shown). In
otherexperiments, the addition of5 ,UM arachidonic acid was asso-
ciated with a 37% reduction in apoptosis induced by the combina-
tion (data not shown), suggesting that the combination ofQ and P
does indeed perturb elements of the PLA2 signal transduction
pathway, the effects ofwhich are partially reversed by the addition
ofexogenous arachidonic acid.
Effect of lovastatin and quinacrine on PC-3
-4 -2 0 2 4 6 8 10 12 14 16 To confirm the hypothesis that quinacrine can enhance the action
Time (days) of inhibitors of ras protein function, we also used lovastatin, a
competitive inhibitor of HMGCoA reductase and an inhibitor of
Figure 5 The effect ofquinacrine and paclitaxel on the growth of DU145 ras signalling (Hohl and Lewis, 1995),concurrently with Q against
xenografts in nude mice. Treatment groups (and their respective doses) are: PC-3 cells, and assessed the combination for synergy with Chou
controls (0, sterile water); quinacrine alone (E, 100 mg kg-'), paclitaxel alone analysis. In general, the results suggest that this combination also
(A, 1 mg kg-'), quinacrine (50 mg kg-') + paclitaxel (0.5 mg kg-')
concurrently (v) and quinacrine (100 mg kg-') + paclitaxel (1 mg kg-') has synergistic effects (data not shown). For lovastatin concentra-
sequentially on alternate days (*). Time (days) is plotted along the abscissa, tions of 1 ,UM, all concentrations ofQ (0.1-1O gM) were synergistic
and tumour size (mm3) along the ordinate. Treatment began after mice were in inhibiting growth of PC-3 cells, while for lovastatin concentra-
randomized to assigned groups 5 days after cells were implanted
subcutaneously in both flanks. Error bars indicate the s.e.m. (n = 7-9 mice tions lower or higher than 1 ,UM, some ratios suggested mild
for each group). The arrow represents the start of treatment synergy and others suggested mild antagonism (data not shown).
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Table 2 Combination effects of quinacrine (Q) and paclitaxel (P) in various
non-constant concentration ratios against PC-3, PC-3M and DU145
Q (gm) P (nM) Combination index
PC-3 PC-3M DU145
0.1 0.5 6.37+ 5.85 19.6 + 18.7 0.22 ± 0.06
0.1 1 51.2 ±50.3 38.8 ±37.4 0.31 ± 0.12
0.1 5 6.35 + 6.06 6.52 ± 3.23 0.84 ± 0.26
0.1 10 0.99±0.64 1.20±0.04 0.37±0.04
0.1 50 1.93+0.88 1.83±0.21 1.25±0.12
0.5 0.5 24.5+ 18.3 20.8 + 18.7 0.61 ± 0.07
0.5 1 2.94 ± 0.87 2.54 ± 0.97 0.82 ± 0.25
0.5 5 0.56 ± 0.24 0.36 ± 0.06 1.33 ± 0.36
0.5 10 0.53 ±0.18 0.29 ±0.03 0.41 ± 0.04
0.5 50 1.51 ±0.47 0.79±0.19 1.31 ±0.17
1 0.5 1.57 ± 0.55 1.58 ± 0.71 3.17 ± 1.12
1 1 1.14±0.44 1.07±0.20 2.73±1.37
1 5 0.46 ±0.10 0.71 + 0.25 1.74± 0.45
1 10 0.43 ± 0.07 0.51 ± 0.04 0.56 ± 0.09
1 50 1.04±0.15 1.27±0.17 1.47±0.17
5 0.5 0.77±0.10 0.60±0.17 0.73±0.07
5 1 0.81 + 0.11 0.60 ±0.16 0.80 ±0.05
5 5 0.77+0.09 0.70±0.15 0.93±0.11
5 10 0.84 ± 0.01 0.80 ± 0.08 0.68 ± 0.05
5 50 1.32±0.15 1.72±0.17 1.39±0.17
10 0.5 0.39 ± 0.15 0.46 ± 0.08 0.51 ± 0.03
10 1 0.38±0.14 0.50±0.13 0.52±0.02
10 5 0.41 ±0.15 0.45±0.10 0.64±0.06
10 10 0.41 ±0.17 0.45±0.10 0.55±0.02
10 50 0.61 + 0.22 0.61 ± 0.09 0.99 ± 0.06
Combination index (Cl) >1, = 1 and <1 indicate synergism, additive effect and
antagonism respectively. Cl values are reported ± s.e.m.
Activity of paclitaxel and quinacrine against xenografts
Using RMANOVA, a statistically significant difference (P < 0.05,
q = 5.06, Student-Newman-Keul's method) was found between
the QP combination and the P alone group, suggesting that the
combination was truly synergistic in vivo (Figure 5). In PC-3 and
PC-3M xenografted mice, no differences between any ofthe treat-
ment arms were seen (data not shown).
Toxicity of paclitaxel and quinacrine
Other than a yellow pigmentation associated with Q treatment,
noticeable after about 3 days, no obvious toxicity resulted from the
combination ofQ and P. Foreach group, the mean weight loss was
less than 5% over the entire treatment period.
DISCUSSION
We have shown that quinacrine and paclitaxel appear to act syner-
gistically in inhibiting the in vitro growth of three hormone-
independent human prostate cancer cell lines, PC-3, PC-3M and
DU145. Our initial observations suggested that this synergy was
most consistent at higher quinacrine concentrations (5-10 gM),
raising the possibility that a threshold concentration ofquinacrine
is required for full expression of synergy. As PLA2 has a role in
many signal transduction pathways, we speculate that exceeding
such a threshold may be required for suppression of its functions.
Synergy was seen at quinacrine concentrations as low as 0.1 gM,
indicating that the exact combination ratio ofthese drugs may not
be an important determinant of their synergistic activity. Synergy
was also seen in DU145-bearing mice, where the combination
inhibited the growth of DU145 tumour size more effectively than
either quinacrine or paclitaxel alone (Figure 5), the differences
being statistically significantby RMANOVA (Heitjan et al, 1993),
indicating true synergy. This statistical method takes into account
the change in tumour size with time, similar to the way that all
survival time for patients until the point ofcensorship is included
in survival analyses in human trials. Although at half the dose
intensity of each drug given alone, sequential treatment also
appeared to inhibit tumour growth better than either drug alone,
supporting the idea ofsynergy for the combination.
Synergistic activity was seen in DU145-bearing mice, despite
our inability to keep to schedule owing to the development of
venous thromboses in the tail veins from paclitaxel treatment. We
therefore reasoned that synergy should still occur when the
frequency ofpaclitaxel treatment was reduced. We chose PC-3 and
PC-3M to test whether different scheduling would affect synergy,
because we wanted to screen the combination against different cell
lines andbecause the in vitro studies had suggested that the combi-
nation of quinacrine and paclitaxel was synergistic to a similar
degree in each cell line, indicating that the actual cell line was
unlikely to be important. However, we were surprised to find that
no growth-inhibitory effect for any ofthe treatment arms was seen
in PC-3- or PC-3M-bearing mice. The reasons for this are not
clear, in view ofclear synergy demonstrated for these cell lines in
vitro. We speculate that treatment schedule may play an important
role in the demonstration of synergy in vivo between quinacrine
and paclitaxel, but are unable to make this conclusion because
different cell lines were used.
Chou analyses can be difficult to interpret. In particular, the
high CIs seen with the combination of either 0.1 JIM or 0.5 gM
quinacrine and 0.1 nm or 0.5 nM paclitaxel (Table 2) suggest
marked antagonism, but these were also accompanied by large
standard errors, suggesting that these results could have occurred
by chance. From Table 2, CIs > 1 (indicating antagonism) tend to
occur at ineffective concentrations of both drugs when used as
single agents. This may result from the initial need to demonstrate
sigmoid dose-response curves for each drug alone in a Chou
synergy analysis, so the effect of low or ineffective drug doses
may have a disproportionate impact on the conclusion.
Consequently, small variations at the flat parts of the sigmoid
dose-response curve, normally accepted as part of the limitations
of the experimental procedure, can cause exaggerated interpreta-
tions of antagonism. Other investigators (Chou et al, 1993) have
avoided this problem by choosing a fixed ratio ofdrug concentra-
tions for testing synergy. However, this approach may have less
clinical relevance because drug concentrations change with time in
vivo. It is for this reason that we chose to test for synergy with
non-constant ratios ofboth drugs.
The relative dose and effect of drugs used in synergy experi-
ments are critical. Synergy can be shown mathematically with the
Chou equation (Chou, 1991; Chou and Chou, 1987), ifdrug doses
in combination are 50% of doses ofeach drug alone, provided the
effect of the combination is equal to or better than for each drug
alone (see Methods). In the apoptosis experiments, although the
degree of apoptosis induced by the combination looked qualita-
tively less than for either quinacrine orpaclitaxel alone (Figure 4),
much less than 50% of the dose of each agent was used.
Quantitating the apoptosis by spectophotometric means would
not have been helpful, because both the drug doses and, as it
happened, the degree of apoptosis, were different. By the ELISA
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method, however, we were able to show quantitatively that there
was at least additive activity for the combination in inducing apo-
ptosis. The finding that arachidonic acid can partially reverse the
apoptosis induced by the combination ofquinacrine and paclitaxel
suggests involvement of the PLA2 pathway. However, it would be
simplistic to suggest that this was also evidence for the mechanism
of synergy between quinacrine and paclitaxel, because both drugs
have other documented actions. Further, ras also has other func-
tions than progressing to PLA2 activation (see Khosravi-Far and
Der, 1994 for review), and PLA, itself is activated by other path-
ways (see Chang et al, 1987 for review). Nevertheless, the obser-
vation that lovastatin, another inhibitor of ras isoprenylation and
function (Hohl and Lewis, 1995; Ruch et al, 1993), has synergistic
activity in combination with quinacrine suggests that the rasIPLA,
pathway might be a fruitful target for anti-cancer therapy.
Quinacrine enhances the action of paclitaxel, but the exact
mechanism of action is unclear and may result from reasons other
than its effect on the ras signalling pathway. Ford et al (1989)
showed that quinacrine was able to reverse some of the effects
of the mdr phenotype in doxorubicin-resistant MCF-7/DOX cells.
However, mdrl mRNA levels in primary prostate cancer, while
common, are expressed at low levels as determined by RNA-
polymerase chain reaction (PCR) (Siegsmund et al, 1994).
Consequently, reversal of mdr phenotype effects by quinacrine
may not play a major role in our results. Others (Zidovetzki et al,
1990) have found that quinacrine can alter membrane phospho-
lipid function. This may be advantageous in that the non-specific
nature ofthe disruption could also theoretically cause perturbation
of ras, as well as PLA,, function, both of which require relocation
to the plasma membrane in order to be activated.
The prevalence ofras mutations in prostate cancer is ofthe order
of 4% in American men and 25% in Japanese men (Isaacs et al,
1994). However, as these estimates were based on a spectrum of
disease, from latent carcinoma to metastatic disease, the true inci-
dence in HRPC is unknown. Because ras has been implicated in the
progression to hormone-resistant disease (Voeller et al, 1991), and
transfection of dominant-negative H-ras mutants into PC-3 cells
has been shown to be very effective in inhibiting growth (Ogiso et
al, 1994), further investigation on the role of ras in the develop-
ment and growth ofmetastatic prostate cancer is warranted.
While a number of ras pathway inhibitors are presently in early
clinical trials, a certain amount of clinical experience with pacli-
taxel and quinacrine already exists, and it seems reasonable to use
these drugs for initial clinical trials to test the concept of
combining ras/PLA, pathway inhibitors. The most clinically
useful steady-state concentrations of quinacrine and paclitaxel
associated with synergy may be around 0.5 ,uM and 5-10 nm
respectively. As short infusions of paclitaxel at typical clinical
doses (> 100 mg m-2) are associated with much higher concentra-
tions (Jamis-Dow et al, 1993) than represented by our in vitro
studies, the conditions for synergy appear easily achievable.
Further, because synergy was seen over a range ofdrug concentra-
tion ratios, faithful duplication of the in vitro conditions for
synergy may not be required. Peak plasma concentrations of up to
140 ng ml-' (about 0.32 gM) for quinacrine are possible on a stan-
dard malaria regimen (Shannon et al, 1944), suggesting that a
convenient design of a clinical trial for the combination of
quinacrine and paclitaxel might employ chronic oral dosing for
quinacrine together with standard doses and scheduling of pacli-
taxel. The significance of such a combination, if it proves to have
activity in the clinical setting, lies in the possible improvement in
toxicity profile over such combinations as estramustine and pacli-
taxel for prostate cancer (Hudes et al, 1995), as well as its potential
application in the treatment of other ras-associated tumours, such
as pancreatic and thyroid cancer.
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